
Novo Nordisk: positive data in hemophilia
(CercleFinance.com) - Novo Nordisk reported positive interim results from the FRONTIER3 phase 3 trial in 70 children (aged one to 11 years) with inhibitor and non-inhibitor hemophilia A, at the 18th EAHAD annual congress in Milan.
The data showed that Mim8 was well tolerated and effective in children with hemophilia A with and without inhibitors, with 74.3% of children on once-weekly Mim8 prophylaxis experiencing no treated bleeds.
Novo Nordisk expects Mim8 to be submitted to regulatory authorities during 2025. Data from the ongoing phase 3 FRONTIER program will be published at upcoming congresses and in publications in 2025 and 2026.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The data showed that Mim8 was well tolerated and effective in children with hemophilia A with and without inhibitors, with 74.3% of children on once-weekly Mim8 prophylaxis experiencing no treated bleeds.
Novo Nordisk expects Mim8 to be submitted to regulatory authorities during 2025. Data from the ongoing phase 3 FRONTIER program will be published at upcoming congresses and in publications in 2025 and 2026.
Copyright (c) 2025 CercleFinance.com. All rights reserved.